# Safety & Immunogenicity of Booster SARS-CoV-2 Vaccine (Vero Cell)

> **NCT05172193** · PHASE2 · UNKNOWN · sponsor: **PT. Kimia Farma (Persero) Tbk** · enrollment: 600 (estimated)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** SARS-COV-2 Vaccine (Vero Cell-Sinopharm) Inactivated

## Key facts

- **NCT ID:** NCT05172193
- **Lead sponsor:** PT. Kimia Farma (Persero) Tbk
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-12-31
- **Primary completion:** 2023-09-30
- **Final completion:** 2023-09-30
- **Target enrollment:** 600 (ESTIMATED)
- **Last updated:** 2022-09-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05172193

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05172193, "Safety & Immunogenicity of Booster SARS-CoV-2 Vaccine (Vero Cell)". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05172193. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*